• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Gilead Sciences

Gilead Sciences

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. MOLOGEN AG: New Strategic Orientation, Successful Capital Measures and Notable Study Progress in 2016

    MOLOGEN AG: New Strategic Orientation, Successful Capital Measures and Notable Study Progress in 2016

  2. Antifungal Drugs: $16.1 Billion Technologies and Global Markets Report 2017-2021 - Research and Markets

    Antifungal Drugs: $16.1 Billion Technologies and Global Markets Report 2017-2021 - Research and Markets

  3. Cystic Fibrosis Market 2015-2022 - Global Strategic Business Report 2017 - FDA Approves Vertex's ORKAMBI - Research and Markets

    Cystic Fibrosis Market 2015-2022 - Global Strategic Business Report 2017 - FDA Approves Vertex's ORKAMBI - Research and Markets

  4. UPDATE: Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought

    UPDATE: Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought

  5. Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought

    Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought

  6. UPDATE: Pharma says high prices fund drug development -- but this study finds otherwise

    UPDATE: Pharma says high prices fund drug development -- but this study finds otherwise

  7. Global $392.80 Billion Nanomedicine Market Drivers, Opportunities, Trends, and Forecasts, 2023 - Research and Markets

    Global $392.80 Billion Nanomedicine Market Drivers, Opportunities, Trends, and Forecasts, 2023 - Research and Markets

  8. SynCardia Names New VP of Manufacturing and Facilities

    SynCardia Names New VP of Manufacturing and Facilities

  9. UPDATE: This titanic stock market has that sinking feeling

    UPDATE: This titanic stock market has that sinking feeling

  10. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

12345

©2017 Morningstar Advisor. All right reserved.